Clinical Trials

Current Studies

Acromegaly Study CSOM230C2402
The purpose of this clinical research study is to determine if the investigational drug SOM230 (pasireotide) is more effective in treating acromegaly than the presently available somatostatin analogs octreotide and lanreotide. Participants must be at least 18 years old and have active acromegaly, not controlled by maximal octreotide or lanreotide dose. An "investigational drug" is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3
Participation Duration: Participants will be asked to visit the study center 7 times over 7 months to receive treatment once a month.
Protocol Number: CSOM230C2402

Past Studies

The Acromegaly Study, Protocol Number: CSOM230C2305 is now closed.

Learn more

If interested, contact the Study Coordinator via email at amunson1(at)jhmi(dot)edu or phone at 410-502-0033 or Roberto Salvatori, MD, Principal Investigator via phone at 410-955-3921 or via email at salvator(at)jhmi(dot)edu.